SciClone Pharmaceuticals, Inc. (SCLN) reported net income for the fourth quarter of $1.9 million or $0.03 per share, compared to $11.6 million or $0.19 per share for the year-ago quarter.
Excluding items, adjusted net income for the fourth quarter was $2.0 million or $0.04 per share, compared to $11.4 million or $0.19 per share in the prior year quarter.
Total net revenue for the fourth quarter fell to $33.14 million form $39.68 million a year ago.
Analysts polled by Thomson Reuters expected the company to earn $0.12 per share on revenue of $35.30 million for the fourth quarter. Analysts' estimates typically exclude special items.
Looking forward to full year 2013, the company forecast revenue of $150 to $155 million and adjusted earnings of $0.66 and $0.72 per share. Analysts currently expect the company to earn $0.65 per share on revenue of $153.07 million for the full year 2013.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.